Syncona Limited Publication of 2022 Annual Report & Notice of AGM (7952Q)
30 Junio 2022 - 03:00AM
UK Regulatory
TIDMSYNC
RNS Number : 7952Q
Syncona Limited
30 June 2022
Syncona Limited
Publication of 2022 Annual Report and Notice of Annual General
Meeting
30 June 2022
Syncona Ltd, a leading healthcare company focused on founding,
building and funding a portfolio of global leaders in life science,
today announces that it has published its Annual Report and
Accounts for the year ended 31 March 2022 ("2022 Annual Report")
and its Notice of the Annual General Meeting 2022.
In compliance with Listing Rule 9.6.1, these documents have
today been submitted to the National Storage Mechanism and will
shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
The Notice of the Annual General Meeting 2022 is available on
Syncona's website at
https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/
. The 2022 Annual Report is available on Syncona's website at
https://www.synconaltd.com/investors/results-and-presentations/ .
Printed copies of these documents are also being posted to
shareholders where requested.
Syncona's Annual General Meeting will be held at 10:30am on 2
August 2022 at the offices of Citco Fund Services (Guernsey)
Limited, Arnold House, St Julian's Avenue, St. Peter Port,
Guernsey, GY1 3RD. Shareholders are encouraged to ensure that their
votes are counted at the 2022 Annual General Meeting by appointing
the chair of the 2022 Annual General Meeting as their proxy in line
with the procedures set out in the Notice of Annual General
Meeting.
Enquiries
Syncona Ltd
Natalie Garland-Collins / Fergus Witt
Tel: +44 (0) 7714 916615
About Syncona
Syncona's purpose is to invest to extend and enhance human life.
We do this by founding and building companies to deliver
transformational treatments to patients in areas of high unmet
need.
Our strategy is to found, build and fund companies around
exceptional science to create a diversified portfolio of 15-20
globally leading healthcare businesses for the benefit of all our
stakeholders. We focus on developing treatments for patients by
working in close partnership with world-class academic founders and
management teams. Our balance sheet underpins our strategy enabling
us to take a long-term view as we look to improve the lives of
patients with no or poor treatment options, build sustainable life
science companies and deliver strong risk-adjusted returns to
shareholders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAFIFEDRRIIVIF
(END) Dow Jones Newswires
June 30, 2022 04:00 ET (08:00 GMT)
Syncona (LSE:SYNC)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Syncona (LSE:SYNC)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024